AYTU - アイトゥ・バイオサイエンス (Aytu BioScience Inc.) アイトゥ・バイオサイエンス

 AYTUのチャート


 AYTUの企業情報

symbol AYTU
会社名 Aytu BioScience Inc (アイトゥ・バイオサイエンス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Aytu BioScience Inc. is a commercial-stage healthcare company focused on acquiring developing and commercializing products in the field of urology. The Company focuses on hypogonadism prostate cancer urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide) a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company''s pipeline includes MiOXSYS an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone) a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company through its wholly-owned subsidiary Nuelle Inc. is focused on women’s sexual wellbeing and intimacy.   アイトゥ・バイオサイエンスは米国のバイオ医薬品企業。泌尿器科の疾患に対する治療薬の開発・商業化に従事する。性腺機能低下症、泌尿器科のがん、男性不妊症、男性の健康における医療ニ―ズに焦点を置く。テストステロン製剤の鼻用ゲル「Natesto」、前立腺がん検出用の「ProstaScint」を開発する。本社所在地はコロラド州イ―グルウッド。   Aytu BioScience, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Natesto, Tuzistram, ZolpiMist and MiOXSYS. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.
本社所在地 373 Inverness Parkway Suite 206 Englewood CO 80112 USA
代表者氏名 Joshua R. Disbrow ジョシュア・R・ディスブロー
代表者役職名 Chief Executive Officer Director 最高経営責任者(CEO)
電話番号 +1 720-437-6580
設立年月日 37469
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 63人
url www.aytubio.com
nasdaq_url https://www.nasdaq.com/symbol/aytu
adr_tso
EBITDA EBITDA(百万ドル) -15.25294
終値(lastsale) 1.19
時価総額(marketcap) 2143679.09
時価総額 時価総額(百万ドル) 11.87358
売上高 売上高(百万ドル) 3.66012
企業価値(EV) 企業価値(EV)(百万ドル) 4.86105
当期純利益 当期純利益(百万ドル) -10.18786
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Aytu Bioscience Inc revenues increased 14% to $3.7M. Net loss decreased 55% to $10.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Derivative income increase from $213K to $4M (income) Interest (expense) decrease of 70% to $749K (expense).

 AYTUのテクニカル分析


 AYTUのニュース

   Aytu BioScience EPS beats by $0.01, beats on revenue (NASDAQ:AYTU)  2020/10/06 20:07:28 Seeking Alpha
Aytu BioScience (NASDAQ:AYTU): Q4 GAAP EPS of -$0.03 beats by $0.01. Revenue of $14.86M (+764.0% Y/Y) beats by $3.62M. Shares +19.55%. Press Release
   Aytu BioScience's Earnings Outlook  2020/09/23 10:26:00 Benzinga
On Thursday, September 24, Aytu BioScience (NASDAQ: AYTU) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings …
   Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study  2020/08/17 12:00:00 Yahoo Finance
Delivery of Investigational Endotracheal Ultraviolet-A Light Catheter Devices Enables Near-Term Initiation of Planned Clinical Studies in Severely Ill COVID-19 PatientsENGLEWOOD, CO / ACCESSWIRE / August 17, 2020 / Aytu BioScience, Inc.
   Thinking about buying stock in Citius Pharmaceuticals, Aytu Bioscience, Applied DNA Sciences, Royal Caribbean Cruises, or American Airlines?  2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, AYTU, APDN, RCL, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Strong Buy  2020/06/25 16:00:04 Yahoo Finance
Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
   Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study  2020/08/17 12:00:00 Yahoo Finance
Delivery of Investigational Endotracheal Ultraviolet-A Light Catheter Devices Enables Near-Term Initiation of Planned Clinical Studies in Severely Ill COVID-19 PatientsENGLEWOOD, CO / ACCESSWIRE / August 17, 2020 / Aytu BioScience, Inc.
   Thinking about buying stock in Citius Pharmaceuticals, Aytu Bioscience, Applied DNA Sciences, Royal Caribbean Cruises, or American Airlines?  2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, AYTU, APDN, RCL, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Strong Buy  2020/06/25 16:00:04 Yahoo Finance
Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
   Edited Transcript of AYTU earnings conference call or presentation 14-May-20 8:30pm GMT  2020/06/25 05:50:32 Yahoo Finance
Q3 2020 Aytu BioScience Inc Earnings Call
   Why Aytu BioScience (AYTU) Stock Might be a Great Pick  2020/06/12 12:47:12 Yahoo Finance
Aytu BioScience (AYTU) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Will All Those Deals Pay Off for Aytu BioScience Stock  2020/06/03 16:54:10 24/7 Wall street
   Aytu BioScience Announces Significant Improvement in Natesto(R) Patient Access in the United States  2020/06/03 12:00:00 Yahoo Finance
ENGLEWOOD, CO / ACCESSWIRE / June 3, 2020 / Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that, as of July 1, 2020, Express Scripts, Inc., ("Express Scripts
   Aytu BioScience Announces $15 Million Debt Retirement  2020/06/01 20:01:00 Yahoo Finance
Company Retires $15M Obligation Assumed with Previously Announced Cerecor Commercial Portfolio Asset Purchase Company's Debt Reduced to Approximately $1 Million ENGLEWOOD, CO / ACCESSWIRE / June 1, 2020 …
   Aytu BioScience Announces Emergency Use Authorization of COVID-19 IgG/IgM Rapid Test  2020/06/01 12:00:00 Yahoo Finance
Fourth FDA Emergency Use Authorization of a COVID-19 IgG/IgM Lateral Flow Rapid Test 1.4 Million Rapid Tests Available for Distribution at Company's Warehouse ENGLEWOOD, CO / ACCESSWIRE / June 1, 2020 …
   The Path to Profitability for Aytu BioScience Stock  2020/05/29 15:35:09 24/7 Wall street

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アイトゥ・バイオサイエンス AYTU Aytu BioScience Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)